

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd Riedl et al.

Serial No.: 10/042,203

ADEMARK OFFICE TO TO TO THE TOTAL TO THE TOTAL TO THE TOTAL TO THE TOTAL TOTAL

Filed: January 11, 2002

Examiner: Rita Desai

For: ω-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE

**INHIBITORS** 

### **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

Based on information from foreign associates, it is believed that at least Iranian No. 26555 and Lebanese No. 6124 are patented applications filed in the English language and registered. Copies of the registration certificates and the applications filed are provided herewith.

Iran Patent No. 26555 was filed on January 13, 2000 and Lebanese Patent No. 6124 was filed on January 12, 2000. Both filing dates are within one year of the effective filing date of this application.

#### **FEES**

No fee is required for this Information Disclosure Statement because:

This Information Disclosure Statement is being filed before the mailing of a first action on the merits after the filing of a Request for Continued Examination Under §1.114.

### **DEPOSIT ACCOUNT**

The Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-

3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard J. Traverso (Reg. No. 30,595)

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 25A

Date: asverba 19, 2002

RJT:lvb

K:\Bayer\25A\IDS 10-25-02.dot

# RECEIVED

NOV 2 0 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known			
Application Number	10/042,203		
Filing Date	January 11, 2002		
First Named Inventor	Bernd Riedl et al.		
Group Art Unit	1625		
Examiner Name	Rita Desai		
Attorney Docket Number	BAYER 25A		

			U.S. PATENT DOCUM	MENTS	
Examiner Initials *	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
•		4,973,675	Israel et al.	11-27-1990	
		6,147,116	Barbachyn et al.	11-14-2000	W
		6,344,476 B1	Ranges et al.	2-5-2002	30 103
		4,111,683	Singer	9-5-1978	100
		5,596,001	Hamanaka	1-21-1997	1901
		5,447,957	Adams et al.	9-5-1995	5/1/0
		6,143,764	Kubo et al.	11-7-2000	
		6,043,374	Widdowson et al.	3-28-2000	
		6,015,908	Widdowson et al.	1-18-2000	
		5,929,250	Widdowson et al.	7-27-1999	
		6,391,917 B1	Petrie et al.	5-21-2002	ľχ
		4,279,639	Okamoto et al.	7-21-1981	X
			(/ \	1	
			V . \	//	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
				/	
				7	
			1		
		A (			X
	1		1	1	


			\\ FOREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Office 3	Number 4 Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Тв
		JP	54-032468		9-3-1979		
	İ	EP	0405233A1		1-2-91		
	<del>                                     </del>	EP	0379915A1		8-1-90		
		EP	0381987A1		8-16-90		
	<u> </u>	EP	0380048A2		8-1-90		
		EP	0264904A2		4-27-88		
		EP	0359148A1		3-21-90		
<del></del>	<del>                                     </del>	EP	0233559B1		8-26-87		
		EP	0230400A2		7-29-87		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.



MOV 2 0 20m2

## TECH CENTER 1600/2010

Please type a plus sign (+) inside this box

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 5

Grou Exam

Compl t if Known

Application Number 10/042,203

Filing Date January 11, 2002

First Named Inventor Bernd Riedl et al.

Group Art Unit 1625

Examiner Name Rita Desai

Attorney Docket Number BAYER 25A

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Publication No. US 2002/0065296 A1, Publication Date: May 30, 2002, Dumas et al.	
		Publication No. US 2002/0062763 A1, Publication Date: May 30, 3003, Macholdt et al.	
		Publication No. US 2002/012831 A1, Publication Date: September 21, 2002, Widdowson et al.	
		Publication No. US 2002/0082255 a1, Publication Date: June 27, 2002, Eastwood	
		Caplus 113:106314, Abstract of JP 2022650, Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove lecuo cyan dye, Noboru Mizukura et al. January 25, 1990.	
		Caplus 113:142130, Abstract of JP 2023337, Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler, Toshihiko Yagi et al., January 25, 1990.	
		Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides Billiary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat, Chemical Life Science, pp. 157-66, 1977.	
		Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments", National Academy of Science of Ukraine, M.V. Kurik et al., pp. 2038-2041, 1996.	
		Caplus 127:273945, "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database", School of Pharmacy and Chemistry, J. C. Dearden, pp. 93-104, 1996	
		Caplus 126:166148, "Iphibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells", James D. Winkler et al., J. Pharmacol. Exp. Ther. Pp. 956,966, 1996.	
		Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives", November 15, 1982.	

	حذ		• • •
Examiner	$\Box$	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\PTO-1449 10-25-02.dot

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

NOV 2 0 20UZ

## TECH CENTER 1600/2003

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/042,203 **Application Number** INFORMATION DISCLOSURE January 11, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Bernd Riedl et al. Group Art Unit 1625 (use as many sheets as necessary) **Examiner Name** Rita Desai Sheet 5 Attorney Docket Number **BAYER 25A** 

				U.S. PATENT DOCU	MENTS	-
Examiner Cite No.1		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan
	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
-						
	-	<del> </del>				
		<del></del>				
	<del> </del>	-				
					/	
	-	<del>                                     </del>			<del>                                     </del>	
					<del>                                     </del>	
		1			/	

				FOREIG	N PATENT DOĆU	MENTS		
Examiner	Cite		oreign Patent Docu		Name of Patencee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.¹	Office 3	Number	Kind Code <sup>5</sup> (if known)	Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T <sub>β</sub>
		EP	0192263B1			8-27-1986		
		EP	0107214A1	$\mathcal{L}\mathcal{T}$	1	5-2-1984		
		WO	0047577/			8-17-2000		
		WO	99/21835	$\mathbf{X}$		5-6-1999		
		WO	99/24635			5-6-1999		
		WO /	00/41698 /		4	7-20-2000		
		wo	00/42012/			7-20-2000		
		wo	01/36403A1			5-25-2001	W	
		wo	96/13682			5-9-1996		
		WO V	99/20617			4-29-1999		
		wo	-96/13632	1		5-9-1996		
		WO	02/24635A2	1		3-28-2002		
		IR	26555					
		LB	6124					

4		 	
ĺ	Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.





Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/042.203 INFORMATION DISCLOSURE January 11, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Bern Riedl et al. Group Art Unit 1625 (use as many sheets as necessary) **Examiner Name** Rita Desai Of 5 Sheet Attorney Docket Number **BAYER 25A** 

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas", Dr. A. Wander, October 15, 1969.	
		Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunization", G. A. Bonwick et al., J. Immunol. Methods, pp. 163-173, 1996.	
		Caplus 127:34137f, "Preparation of quinoline an dquinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation", Kazuo Kubo et al., May 15, 1997.	
		Caplus 131:58658, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas", Miller, Scott, July 1, 1999.	
		Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas", Jacques Dumas, July 1, 1999.	
		Caplus 131:73649b, "Preparation of pyrazolyl arylureas and related compounds as p38kinase inhibitor", Jacques Dumas, July 1, 1999.	
		Joseph V. Simone, "Cecil Textbook of Medicine", 20th Edition, Vol. 1, 2-3-1997. pp. 1004-1010.	
		Cesar Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors", Vol. 37 No. 38, pp. 6947-6950, 1996.	
		Jacqueline E. Van Muijwijk Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A <sub>3</sub> Receptor", J. Ed. Ohem. 2000, 43, pp. 2227-2238, January 3, 2000.	
		Jacques Dumas et al., "1 Phenyl-5-pyrazolyl Greas: Potent and Selective p38 Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, pp. 2051-2054, May 2, 2000.	
		Robert W. Carling et al., "1-(3-Cyanobenxylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D <sub>4</sub> Receptor with Excellent Selectivity over Ion Channels", J. Med. Chem., 1999, 42, pp. 2706-2715.	
		Abstract WO 9822103, May 28, 1998, John Philip Hedge et al.	

Examiner	···	Date	
Signature		Considered	J

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 3 PTO-1449 10-25-02.dot

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



RECEIVED NOV 2 0 2002 TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete if Known		
	Application Number	10/042,203	
INFORMATION DISCLOSURE	Filing Date	January 11, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Bern Riedl et al.	
	Group Art Unit	1625	
(use as many sheets as necessary)	Examiner Name	Rita Desai	
Sheet 5 Of 5	Attorney Docket Number	BAYER 25A	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	т	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		Abstract of DE 3305866A1, August 29, 1984, Dr. Acker Rolf-Dieter et al.		
		Abstract of EP 4931(equivalent 4,240,820), K. Dickore e tal. (1980)		
		Dumas, J "CAS Structure," May 6, 1997, pages 1-29		
		Scott, Bill, "Substructure (Patent Families)", August 11, 1997, pages 1-19.		
		Scott, Bill, "Substructure #2", November 25, 1997, pages 1-3.		
		"Beilstein number" Collection, 28 pages (1997)		
		"Beilstein Collection", 4 pages (1997)		
		Scott, Bill, *Substructure Search, December 2, 1997, pages 1-51.		
		Substructure Search, pages 7-30. (1997)		
	,	Derwent World Patents Index Search, pages 20-26. (1997)		
		Abstract of ER 116,982 (1984)		
		Abstract of EP 676,395 (1995)		
		Abstract of EP 202,538 (1986)		
		Abstract of EP 16,371 (1980)		

Examiner	Date	,
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 4 PTO-1449 10-25-02.dot

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.